Meloxicam in osteoarthritis: A 6-month, double-blind comparison with diclofenac sodium

British Journal of Rheumatology

Volumn 35, Issue SUPPL. 1, 1996, Pages 39-43

  Hosie, J ^a   Distel, M ^b   Bluhmki, E ^b  

^a Great Western Medical   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Diclofenac sodium; Meloxicam; Non steroidal anti inflammatory drugs; Osteoarthritis

Indexed keywords

DICLOFENAC; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN SYNTHASE;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COXITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE DISEASE; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KNEE ARTHRITIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOVEMENT (PHYSIOLOGY); MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE;

EID: 0029868836     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.suppl_1.39     Document Type: Article

References (15)

1. Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy. Arch Intern Med 1987;147:2093-100.
2. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler Chr. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995;44:423-33.
3. Engelhardt G. Meloxicam: a potent inhibitor of COX-2. Data presented at 9th International Conference on Prostaglandins and Related Compounds, Florence, Italy 6-10 June 1994, p. 82.
4. 14C-labelled meloxicam: a new antiphlogistic drug, in man. Abstract presented at the XVIIth ILAR Congress of Rheumatology, Rio de Janeiro, Brazil, 17-23 September 1989.
5. Lund B, Bluhmki E, Distel M. A double-blind placebo controlled study of three different doses of meloxicam with in-patients with osteoarthritis of the knee. Scand J Rheumatol 1994;Suppl 98:abstract no. 117.
6. Martini C, Hunt S. The Nottingham Health Profile. In: McDowell S, Newell C, eds. Measuring health. Oxford University Press, 1981.
7. Tannenbaum H, Esdaile J, Topp JR et al. A double-blind, multicentre, controlled study on diclofenac (Voltaren) and naproxen in patients with rheumatoid arthritis (RA). Curr Ther Res 1984;35:356-63.
8. Todd PA, Sorkin EM. Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1988;35:244-85.
9. Amundsen T, Bleken L, Borkje B et al. Variation in response to naproxen and diclofenac in patients with osteoarthritis. Curr Ther Res 1983;5:792-801.
10. Bellamy N, Buchanan WW, Chalmers A et al. A multicentre study of tenoxicam and diclofenac in patients with osteoarthritis of the knee. J Rheumatol 1993;20:998-1005.
11. García-Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
12. Langman MJS, Well J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
13. Lindén B, Bluhmki E, Distel M. Double-blind randomized comparison of meloxicam and piroxicam in patients with osteoarthritis of the hip. Br J Rheumatol 1995;35(suppl. 1):35-38.
14. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231:232-5.
15. Vane J. Towards a better aspirin. Nature 1994;367:215-6.